Bradley M. Kerr

1.6k total citations
24 papers, 1.4k citations indexed

About

Bradley M. Kerr is a scholar working on Nephrology, Infectious Diseases and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bradley M. Kerr has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Nephrology, 7 papers in Infectious Diseases and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bradley M. Kerr's work include Gout, Hyperuricemia, Uric Acid (8 papers), HIV/AIDS drug development and treatment (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Bradley M. Kerr is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (8 papers), HIV/AIDS drug development and treatment (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Bradley M. Kerr collaborates with scholars based in United States, Japan and France. Bradley M. Kerr's co-authors include Deanna L. Kroetz, Susan M. Klein, R H Lévy, Frank J. Gonzalez, Kenneth E. Thummel, René H. Levy, Poe‐Hirr Hsyu, Bhasker V. Shetty, Stephanie Webber and Barry Quart and has published in prestigious journals such as Hepatology, Antimicrobial Agents and Chemotherapy and Biochemical Pharmacology.

In The Last Decade

Bradley M. Kerr

24 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bradley M. Kerr United States	16	375	366	285	239	226	24	1.4k
E Singlas France	23	198 0.5×	299 0.8×	355 1.2×	143 0.6×	235 1.0×	86	1.4k
Christina L. Aquilante United States	26	829 2.2×	468 1.3×	366 1.3×	103 0.4×	425 1.9×	87	2.3k
Leo Stolk Netherlands	23	164 0.4×	544 1.5×	216 0.8×	152 0.6×	249 1.1×	68	2.4k
Rick Greupink Netherlands	24	163 0.4×	347 0.9×	178 0.6×	40 0.2×	332 1.5×	70	1.4k
Umesh Shukla United States	24	179 0.5×	95 0.3×	152 0.5×	148 0.6×	138 0.6×	69	1.5k
Anne M. Baciewicz United States	15	284 0.8×	250 0.7×	393 1.4×	74 0.3×	189 0.8×	28	1.0k
Zheng Jiao China	27	267 0.7×	663 1.8×	293 1.0×	532 2.2×	274 1.2×	109	1.9k
John Lettieri United States	25	200 0.5×	227 0.6×	114 0.4×	91 0.4×	381 1.7×	77	1.9k
Franck Saint‐Marcoux France	29	93 0.2×	417 1.1×	182 0.6×	187 0.8×	182 0.8×	101	2.0k
Ingegerd Odar‐Cederlöf Sweden	23	293 0.8×	390 1.1×	72 0.3×	156 0.7×	218 1.0×	53	1.7k

Countries citing papers authored by Bradley M. Kerr

Since Specialization

Citations

This map shows the geographic impact of Bradley M. Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley M. Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley M. Kerr more than expected).

Fields of papers citing papers by Bradley M. Kerr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley M. Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley M. Kerr. The network helps show where Bradley M. Kerr may publish in the future.

Co-authorship network of co-authors of Bradley M. Kerr

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley M. Kerr. A scholar is included among the top collaborators of Bradley M. Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley M. Kerr. Bradley M. Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Shen, Zancong, et al.. (2019). Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers. Clinical Pharmacology in Drug Development. 8(5). 657–663. 5 indexed citations

2.

Yang, Chun, Zancong Shen, Bradley M. Kerr, et al.. (2018). Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans. Xenobiotica. 49(7). 811–822. 10 indexed citations

3.

Gillen, Michael, Chun Yang, David M. Wilson, et al.. (2017). Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide. Clinical Pharmacology in Drug Development. 6(4). 363–376. 19 indexed citations

4.

Gillen, Michael, et al.. (2016). Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. Drug Design Development and Therapy. Volume 10. 3555–3562. 24 indexed citations

5.

Shen, Zancong, et al.. (2016). Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study. Drug Design Development and Therapy. Volume 10. 3509–3517. 3 indexed citations

6.

Fleischmann, R., Bradley M. Kerr, Li‐Tain Yeh, et al.. (2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Lara D. Veeken. 53(12). 2167–2174. 81 indexed citations

7.

Xiang, Alan X., Stephen E. Webber, Bradley M. Kerr, et al.. (2007). Discovery of ANA975: An Oral Prodrug of the TLR-7 Agonist Isatoribine. Nucleosides Nucleotides & Nucleic Acids. 26(6-7). 635–640. 31 indexed citations

8.

Horsmans, Yves, Thomas Berg, Jean‐Pierre Desager, et al.. (2005). Isatoribine, an Agonist of TLR7, Reduces Plasma Virus Concentration in Chronic Hepatitis C Infection *. Hepatology. 42(3). 724–731. 195 indexed citations

9.

Hsyu, Poe‐Hirr, et al.. (2005). Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharmaceutics & Drug Disposition. 27(2). 61–68. 12 indexed citations

10.

Skowron, Gail, Gifford Leoung, David B. Hall, et al.. (2004). Pharmacokinetic Evaluation and Short-Term Activity of Stavudine, Nevirapine, and Nelfinavir Therapy in HIV-1???Infected Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 35(4). 351–358. 10 indexed citations

11.

Hsyu, Poe‐Hirr, Yazdi K. Pithavala, Merril Gersten, C A Penning, & Bradley M. Kerr. (2002). Pharmacokinetics and Safety of an Antirhinoviral Agent, Ruprintrivir, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 46(2). 392–397. 32 indexed citations

12.

Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(8). 2405–2405. 1 indexed citations

13.

Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(4). 1086–1093. 107 indexed citations

14.

Jackson, Kimberley, Sara Rosenbaum, Bradley M. Kerr, et al.. (2000). A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical Trial. Antimicrobial Agents and Chemotherapy. 44(7). 1832–1837. 30 indexed citations

15.

Kerr, Bradley M., Kenneth E. Thummel, Susan M. Klein, et al.. (1994). Human liver carbamazepine metabolism. Biochemical Pharmacology. 47(11). 1969–1979. 371 indexed citations

16.

Kroetz, Deanna L., Bradley M. Kerr, Lynne V. McFarland, et al.. (1993). Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clinical Pharmacology & Therapeutics. 53(3). 306–315. 21 indexed citations

17.

Farwell, Jacqueline R., et al.. (1993). Stiripentol in Atypical Absence Seizures in Children: An Open Trial. Epilepsia. 34(2). 305–311. 54 indexed citations

18.

Kerr, Bradley M., et al.. (1991). Carbamazepine Dose Requirements During Stiripentol Therapy: Influence of Cytochrome P‐450 Inhibition Stiripentol. Epilepsia. 32(2). 267–274. 35 indexed citations

19.

Kerr, Bradley M., Allan E. Rettie, A. Craig Eddy, et al.. (1989). Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clinical Pharmacology & Therapeutics. 46(1). 82–93. 70 indexed citations

20.

Levy, René H. & Bradley M. Kerr. (1989). Pharmacokinetics of Old, New, and Yet‐to‐Be‐Discovered Antiepileptic Drugs. Epilepsia. 30(s1). S35–41; discussion S64. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact